Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

23 nov. 2015 08h00 HE | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Responds to Recent Complete Response Letter From the FDA for the Single-Dose, Preservative-Free Vial of Makena(R)

WALTHAM, Mass., Nov. 23, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that it responded to the U.S. Food and Drug Administration (FDA), providing the information...
18 nov. 2015 17h43 HE | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Receives Complete Response Letter From FDA for Single-Dose, Preservative-Free Vial of Makena(R) (hydroxyprogesterone caproate injection)

WALTHAM, Mass., Nov. 18, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for its...
11 nov. 2015 08h16 HE | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals to Participate in the Jefferies Autumn 2015 Global Healthcare Conference in London

WALTHAM, Mass., Nov. 11, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the Jefferies Autumn...
03 nov. 2015 07h30 HE | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Reports Third Quarter 2015 Financial Results

Achieves non-GAAP quarterly revenue of $103.5 million and adjusted EBITDA of $52.8 million Provides new updates on Makena next generation development programs Closes acquisition and initiates...
28 oct. 2015 07h00 HE | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Announces Head-to-Head Phase 3 Clinical Trial Evaluating Feraheme(R) in Adults With Iron Deficiency Anemia

WALTHAM, Mass., Oct. 28, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it has commenced start-up activities for its head-to-head Phase 3 clinical trial...
20 oct. 2015 08h00 HE | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals to Host Conference Call on November 3, 2015 at 8:00 a.m. ET to Discuss Financial Results for the Quarter and Nine Months Ended September 30, 2015

WALTHAM, Mass., Oct. 20, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it will report unaudited consolidated financial results for the quarter and nine months ended...
01 sept. 2015 16h00 HE | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Sept. 1, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will discuss AMAG's business and financial outlook, strategy and...
24 août 2015 16h00 HE | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Appoints Joseph Vittiglio as General Counsel and Secretary

WALTHAM, Mass., Aug. 24, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that Joseph Vittiglio has joined the company as senior vice president, general counsel and...
17 août 2015 16h00 HE | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Completes Acquisition of Cord Blood Registry

Expands company's growing maternal health business Transaction expected to be immediately accretive Company anticipates seamless integration and is well positioned for future...
12 août 2015 16h01 HE | Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals Announces Pricing of Private Offering of $500 Million of Senior Notes Due 2023

WALTHAM, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that it has priced its offering of $500 million aggregate principal amount of 7.875% Senior...

Page précédente